Bio-Rad Laboratories, Inc. BIOB
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.52% | -0.09% | 1.14% | 3.85% | 0.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.52% | -0.09% | 1.14% | 3.85% | 0.51% |
| Cost of Revenue | -2.29% | -0.36% | 1.18% | 11.49% | 5.80% |
| Gross Profit | 3.06% | 0.14% | 1.11% | -2.87% | -3.84% |
| SG&A Expenses | 5.48% | 2.02% | 1.68% | 6.26% | 2.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.06% | 0.66% | -0.68% | 5.90% | 0.22% |
| Operating Income | 14.12% | -5.70% | 43.93% | -13.38% | 3.03% |
| Income Before Tax | 224.96% | 30.94% | -927.10% | 202.23% | -150.03% |
| Income Tax Expenses | 189.80% | 77.44% | -938.66% | 208.34% | -142.80% |
| Earnings from Continuing Operations | 234.13% | 16.87% | -923.59% | 200.59% | -152.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 234.13% | 16.87% | -923.59% | 200.59% | -152.34% |
| EBIT | 14.12% | -5.70% | 43.93% | -13.38% | 3.03% |
| EBITDA | 5.88% | -3.31% | 21.45% | -5.63% | 6.96% |
| EPS Basic | 234.85% | 18.96% | -953.64% | 204.39% | -154.34% |
| Normalized Basic EPS | 8.81% | 8.39% | -6.89% | 9.96% | 9.30% |
| EPS Diluted | 234.02% | 18.68% | -953.83% | 204.23% | -154.41% |
| Normalized Diluted EPS | 8.14% | 8.13% | -6.85% | 9.82% | 9.44% |
| Average Basic Shares Outstanding | -0.53% | -1.76% | -3.52% | -3.65% | -3.67% |
| Average Diluted Shares Outstanding | 0.08% | -1.52% | -3.57% | -3.52% | -3.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |